AMENDMENTS TO THE CLAIMS

1. (Original) Use of an Interleukin 1 receptor antagonist (IL-1Ra) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal.

2. (Original) The use according to claim 1, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant protein (rIL-1Ra).

3. (Original) The use according to any of the preceding claims, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra).

4. (Currently Amended) The use according to ~~any of the preceding claims~~ claim 1, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).

5. (Currently Amended) The use according to ~~any of the preceding claims~~ claim 1, wherein the medicament is adapted for parenteral administration.

6. (Original) Use of pyrrolidinedithiocarbamate (PDTC) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal.

7. (Original) The use according to claim 6, wherein the medicament is adapted for parenteral administration.

8. (Original) A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of an Interleukin 1 receptor antagonist (IL-1Ra).

9. (Original) The method according to claim 8, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant protein (rIL-1Ra).

10. (Original) The method according to 9, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra).

11. (Original) The method according to claim 8, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).

12. (Original) The method according to claim 8, wherein the medicament is adapted for parenteral administration.

13. (Original) A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of pyrrolidinedithiocarbamate (PDTC).

14. (Original) The method according to claim 13, wherein the medicament is adapted for parenteral administration.